Results 131 to 140 of about 13,526 (188)

Long-term safety and pulmonary function stabilization with nintedanib in systemic sclerosis-associated interstitial lung disease, 2020-2025: a real-world retrospective study from a reference centre. [PDF]

Rheumatol Int
Panopoulos S, Poulia V, Vlachogiannis N, Bournia VK, Tektonidou MG, Sfikakis PP.   +5 more
europepmc   +1 more source

Continued Nintedanib Treatment in Children and Adolescents With Fibrosing ILDs: Data From InPedILD-ON. [PDF]

Pediatr Pulmonol
Deterding R, Young LR, DeBoer EM, Warburton D, Cunningham S, Schwerk N, Brown KK, Koucký V, Weinman JP, Simmons J, Dumistracel M, Jantzen F, Gahlemann M, Griese M, InPedILD‐ON trial investigators.   +14 more
europepmc   +1 more source

Nerandomilast (BI 1015550) attenuating pulmonary fibrosis in a mouse model of rheumatoid arthritis-associated interstitial lung disease by modulating the TGF-β1/PI3K/Akt signaling pathway. [PDF]

J Thorac Dis
Wang X, Liu X, Zhong X, Tang L.
europepmc   +1 more source

Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells. [PDF]

Cell Death Dis
Karnan S, Ota A, Hasan MN, Hyodo T, Jahan N, Murakami H, Shihan MTA, Hanamura I, Quang Vu L, Riku M, Ito H, Kaneko Y, Lin Y, Wahiduzzaman M, Rahman ML, Inaguma S, Matsui T, Konishi H, Tsuzuki S, Hosokawa Y.   +19 more
europepmc   +1 more source

Impact of Severe COVID-19 on Interstitial Lung Disease in Autoimmune Systemic Diseases. [PDF]

Respirol Case Rep
Ferri C, de Pinto M, Murdaca G, De Luca G, Beigi DMR, Caira V, Foti R, Cito A, Naclerio C, Luppino JME, Spinella A, Orlandi M, Batani V, Lumetti F, Prampolini F, Varcasia G, Foti R, Riccieri V, Iannone F, Antonelli A, Giuggioli D, COVID‐19 and Autoimmune Systemic Diseases Italian Study Group.   +21 more
europepmc   +1 more source

Prophylactic Effects of Combined Bosentan and Nintedanib on Early Post-Traumatic Joint Contracture Formation in a Rat Model. [PDF]

J Clin Med
Wegner E, Warnke D, Buschmann V, Pirkl A, Betz M, Ritz U, Mühlschlegel TS, Dietz SO, Gercek E, Baranowski A.   +9 more
europepmc   +1 more source

Hepcidin as a Biomarker of Response to Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis. [PDF]

J Clin Med
Yilmaz Gunes G, Çoban H, Erel F, Akış Yılmaz M, Sarioglu N, Colak M, Yumrukuz Senel M.   +6 more
europepmc   +1 more source

Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease: A Pulmonary Perspective on Recent Guidelines. [PDF]

Adv Ther
Ozduygu G, Kaenmuang P, Guedes ABF, Amaral AF, Chaudhuri N.   +4 more
europepmc   +1 more source

Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from the German Network for SSc cohort. [PDF]

Arthritis Res Ther
Filla T, Micu A, Hansen L, Grinberg I, Deicher FS, Lahu LM, Matei AE, Düsing C, Riemekasten G, Blank N, Alberding A, Schmalzing M, Ehrchen J, Günther C, Zeidler G, Jandova I, Keyßer G, Worm M, Müller-Ladner U, Juche A, Susok L, Korsten P, Henes J, Kreuter A, Moinzadeh P, Krieg T, Girke M, Alves M, Hunzelmann N, Distler JHW, Györfi AH.   +30 more
europepmc   +1 more source

Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease. [PDF]

BMC Pulm Med
Goda S, Yamada T, Goto Y, Uda S, Nakao A, Shiotsu S, Kukida Y, Tanimura K, Miyamoto A, Imasato Y, Okada A, Hasegawa I, Date K, Matsui Y, Morito S, Inokuchi N, Osugi S, Kawachi H, Nishioka N, Iwasaku M, Tokuda S, Handa T, Takayama K.   +22 more
europepmc   +1 more source